3Hong JY. Update on pertussis and pertussis immunization [J] . Korean J Pediatr,2010,53(5) :629'{;33.
4Stein-Zamir C, Shoob H, Abramson N, et al. The impact of additional pertussis vaccine doses on disease incidence in children and infants [J]. Vaccine,2011 ,29(2) :207-211.
5Rendi-Wagner P, Tobias J, Moerman L, et al. The seroepidemiology of Bordetella pertussis in Israel-Estimate of incidence of infection [J]. Vaccine,2010 ,28 (19) :3285-3290.
6Heininger U. Update on pertussis in children [J]. Expert Rev Anti Infect Ther,2010,8(2) :163-173.
7Hanson MP, K wan-Gett TS , Baer A, et al. Infant pertussis epidemiology and implications for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis ( Tdap) vaccination [J] . Arch Pediatr Adolesc Med,2011 ,165(7) :647'{;52.
8Donato GM, Goldsmith CS, Paddock CD, et al. Delivery of Bordetella pertussis adenylate cyclase toxin to target cells via outer membrane vesicles [J]. FEBS Letters,2012 ,586( 4) :459465.
9WHO. Vaccine-preventable diseases; monitoring system [R]. Geneva,WHO,2006:20-22.
10Lutsar I, Anca I, Bakir M, et al. Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey-1945 to 2005 [J] . Eur J Pediatr ,2009,168 (4) :407415.
